Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Postmenopausal osteoporosis management.

M Gambacciani1, M Ciaponi

  • 1Department of Reproductive Medicine and Child Development, Piero Fioretti, University of Pisa, Italy. margamba@tin.it

Current Opinion in Obstetrics & Gynecology
|June 29, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SUI in postmenopausal women: advantages of an intraurethral + intravaginal Er:YAG laser.

Climacteric : the journal of the International Menopause Society·2023
Same author

Short-term effects of an erbium/neodymium laser combination in superficial dyspareunia: a pilot study.

Climacteric : the journal of the International Menopause Society·2022
Same author

The VELA experience: a strategic format.

Climacteric : the journal of the International Menopause Society·2020
Same author

Sexual function after vaginal erbium laser: the results of a large, multicentric, prospective study.

Climacteric : the journal of the International Menopause Society·2020
Same author

Er:YAG laser in hysterectomized women with stress urinary incontinence: a VELA retrospective cohort, non-inferiority study.

Climacteric : the journal of the International Menopause Society·2020
Same author

Safety of vaginal erbium laser: A review of 113,000 patients treated in the past 8 years.

Climacteric : the journal of the International Menopause Society·2020
Same journal

Management of hypertensive disorders in pregnancy.

Current opinion in obstetrics & gynecology·2026
Same journal

Updates in group prenatal care research.

Current opinion in obstetrics & gynecology·2026
Same journal

Complex benign gynecology in perimenopause: current evidence and future directions.

Current opinion in obstetrics & gynecology·2026
Same journal

Role of insulin in female reproduction.

Current opinion in obstetrics & gynecology·2026
Same journal

Urinary tract involvement in endometriosis: current evidence and clinical insights into navigating diagnosis and management.

Current opinion in obstetrics & gynecology·2026
Same journal

Updates in ultrasound imaging of adenomyosis and clinical impacts.

Current opinion in obstetrics & gynecology·2026
See all related articles

Estrogen deficiency causes osteoporosis, particularly after menopause. Treatments like hormone replacement therapy, tibolone, and raloxifene help prevent bone loss and reduce fracture risk.

Area of Science:

  • Endocrinology
  • Gerontology
  • Bone Biology

Background:

  • Estrogen deficiency significantly impacts women's health, leading to osteoporosis.
  • Postmenopausal bone loss is a primary driver of osteoporosis.
  • Osteoporosis presents substantial social, physical, and economic challenges.

Purpose of the Study:

  • To review the impact of estrogen deficiency on osteoporosis.
  • To discuss methods for assessing osteoporosis risk.
  • To evaluate therapeutic strategies for preventing postmenopausal bone loss and fractures.

Main Methods:

  • Bone mineral density measurement using dual X-ray absorptiometry.
  • Quantitative bone ultrasound for assessing bone structure and fracture risk.
  • Review of data on hormone replacement therapy, tibolone, and raloxifene efficacy.

Related Experiment Videos

Main Results:

  • Dual X-ray absorptiometry is a standard for bone density measurement.
  • Quantitative bone ultrasound offers radiation-free fracture risk assessment.
  • Hormone replacement therapy, tibolone, and raloxifene effectively prevent bone loss and reduce fractures.

Conclusions:

  • Estrogen deficiency is a major cause of osteoporosis, especially postmenopause.
  • Effective diagnostic tools and therapeutic interventions exist for osteoporosis management.
  • Pharmacological treatments significantly reduce fracture risk in postmenopausal women.